Celebi Breanna Maurine 4
4 · Climb Bio, Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Climb Bio (CLYM) Director Celebi Receives 70,284-Share Option Award
What Happened
Celebi Breanna Maurine, a director of Climb Bio, was granted a derivative award of 70,284 shares (stock option) on June 29, 2026, shown at an exercise/price of $0. The award vests in equal monthly installments beginning June 29, 2026 and continuing until the third anniversary of that date, subject to continued service.
Key Details
- Transaction date and type: 2026-06-29 — Award/Grant (code A) of 70,284 shares at $0.00 (derivative).
- Vesting: Equal monthly installments from June 29, 2026 through the third anniversary (36 months), subject to continued service.
- Ownership after transaction: Not reported; the reporting person disclaims beneficial ownership per the filing.
- Footnote on arrangement: The option is held for the benefit of RA Capital funds and a separately managed account; the reporting person must turn over any net cash or stock received on exercise to the Adviser to offset advisory fees (per filing).
- Filing date/timeliness: Form 4 filed 2026-07-01 for a 2026-06-29 grant — filing appears timely.
Context
This was a compensation-style option grant to a director (not an open-market purchase or sale). Because the reporting person disclaims beneficial ownership and the option is held for institutional RA Capital funds, the grant reflects a managed/institutional arrangement rather than a direct personal investment signal by the director. Grants and option awards to directors are common and do not by themselves indicate immediate buying or selling in the market.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-29+70,284→ 70,284 totalExercise: $13.36Exp: 2036-06-29→ Common Stock (70,284 underlying)
Footnotes (2)
- [F1]The shares underlying the option vest in equal monthly installments from June 29, 2026 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock.